Home Cart Sign in  
Chemical Structure| 196618-13-0 Chemical Structure| 196618-13-0

Structure of Oseltamivir
CAS No.: 196618-13-0

Chemical Structure| 196618-13-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oseltamivir (GS 4104) is an orally active inhibitor of influenza virus neuraminidase (NAI). It effectively inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses, with mean IC50 values of 0.67, 0.9, 1.34, and 13 nM, respectively.

Synonyms: GS 4104

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oseltamivir

CAS No. :196618-13-0
Formula : C16H28N2O4
M.W : 312.40
SMILES Code : O=C(C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1)OCC
Synonyms :
GS 4104
MDL No. :MFCD00953939
InChI Key :VSZGPKBBMSAYNT-RRFJBIMHSA-N
Pubchem ID :65028

Safety of Oseltamivir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Oseltamivir (GS 4104) is an orally administered inhibitor of neuraminidase (NA), targeting influenza viruses. It effectively inhibits various strains including influenza A/H3N2, A/H1N2, A/H1N1, and B viruses, with mean IC50 values of 0.67, 0.9, 1.34, and 13 nM, respectively[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
P3 FVB mouse cochlear explants 450 nM (EC50) 24 hours Oseltamivir phosphate protected mouse cochlear explants from cisplatin-induced outer hair cell death PMC11318337
P3 FVB mouse cochlear explants 505 nM (EC50) 24 hours Oseltamivir carboxylate protected mouse cochlear explants from cisplatin-induced outer hair cell death PMC11318337

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Cisplatin-induced hearing loss model Oral 50 mg/kg 45 minutes before administration, continued for 3 days Oseltamivir significantly reduced cisplatin-induced hearing loss and outer hair cell death PMC11318337

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00949533 Influenza PHASE3 COMPLETED 2025-10-10 Curitiba, 80810-040, Brazil|Sa... More >>o Paulo, 04025-002, Brazil|Sao Paulo, 05508-000, Brazil Less <<
NCT01052961 Influenza|Respiratory Tract In... More >>fections Less << PHASE4 COMPLETED 2025-06-12 The Chinese University of Hong... More >> Kong, Prince of Wales Hospital and Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hksar, Hong Kong Less <<
NCT00884117 Influenza COMPLETED 2025-11-15 Chicago, Illinois, 60655, Unit... More >>ed States|Westmead, New South Wales, 2145, Australia|Bron, 69677, France|Berlin, 14052, Germany|Shatin, Hong Kong|Rotterdam, 3000 CA, Netherlands|Sandnes, 4313, Norway|Krakow, 31-159, Poland Less <<
NCT01249833 Influenza PHASE4 COMPLETED 2025-04-12 Dr. Collette, Vancouver, Briti... More >>sh Columbia, Canada|Dr. Lai, Vancouver, British Columbia, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Moran Medical Centre, Collingwood, Ontario, Canada|Dr. Kanani, Etobicoke, Ontario, Canada|Dr. Herman, London, Ontario, Canada|Milestone Research, London, Ontario, Canada|SKDS Research Inc, Newmarket, Ontario, Canada|Family First Medical Centre, Orleans, Ontario, Canada|Steeple Hill Medical Centre, Pickering, Ontario, L1V 2A6, Canada|Dr. Martyn Chilvers - London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|Dr. Michael O'Mahony - London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|DCTM Clinical Trials Group Ltd., Strathroy, Ontario, Canada|Dr. Gupta, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|Regina Medical Centre, Regina, Saskatchewan, S4P 3X1, Canada Less <<
NCT01130636 Influenza PHASE4 COMPLETED 2025-07-12 DEOEC University of Debrecen, ... More >>Clinic of Obstetrics and Gynecology, Debrecen, H-4032, Hungary|Selye János Hospital, Department of Obstetrics and Gynecology, Komárom, 2921, Hungary Less <<
NCT01179919 Obesity PHASE1|PHASE2 COMPLETED 2025-12-10 TKL Research, Paramaus, New Je... More >>rsey, 07652, United States Less <<
NCT00298233 Influenza|Avian Influenza|Seve... More >>re Influenza Less << PHASE2 COMPLETED 2025-01-10 Changi General Hospital, Singa... More >>pore, Singapore|National University Hospital, National University of Singapore, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Queen Sirikit National Institute of Child Health, Bangkok, Thailand|Siriraj Hospital Mahidol University, Bangkok, Thailand|Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand|Chest Disease Institute, Nonthaburi, Thailand|National Hospital of Pediatrics, Hanoi, Vietnam|National Institute fof Infectious and Tropical Diseases, Hanoi, Vietnam|Children's Hospital #1, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Pediatric Hospital #2, Ho Chi Minh City, Vietnam Less <<
NCT00334529 Influenza PHASE2 COMPLETED 2007-04-10 VA Greater Los Angeles Healthc... More >>are System, Los Angeles, California, 94304, United States|VA Palo Alto Health Care System, Palo Alto, California, 94304, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States|Brooke Army Medical Center, Houston, Texas, United States Less <<
NCT01715909 Influenza PHASE1 COMPLETED 2018-06-17 Lucile Packard Child Hosp; Ped... More >>iatric Pulmonary Division, Palo Alto, California, 94304, United States|The Children's Hospital; Pediatric Infectious Diseases, Aurora, Colorado, 80045, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|SUNY Upstate Medical University, Syracuse, New York, 13210, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Hospital Erasto Gaertner, Curitiba, PR, 81520-060, Brazil|Hospital S?o Lucas da PUCRS, Porto Alegre, RS, 90610-000, Brazil|Graacc-Grupo de Apoio ao adolescente e a crianca com cancer, Sao Paulo, SP, 04023-062, Brazil|Casa de Saúde Santa Marcelina, S?o Paulo, SP, 08270-070, Brazil|Children'S Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|Hospital For Sick Children; Infectious Disease Dept, Toronto, Ontario, M5G 1X8, Canada|McGill University; Montreal Children's Hospital; Oncology, Montreal, Quebec, H4A 3J1, Canada|Hospital Dr. Gustavo Fricke, Vi?a del Mar, 2520000, Chile|Centro Medico Imbanaco, Cali, Colombia|Fundacion Clinica Valle de Lili, Department Rheumatology, Cali, Colombia|Turun yliopistollinen keskussairaala, Turku, 20520, Finland|Charité - Universit?tsmedizin Berlin;Klinik für Allgemeine P?diatrie, Berlin, 13353, Germany|Universitatsklinikum Frankfurt, Frankfurt, 60590, Germany|Dr. Von Haunersches Kinderspital, München, 80337, Germany|Universit?tsklinikum Münster, Münster, 48149, Germany|Universit?tsklinikum Tübingen UNI-Klinik für Kinder- und Jugendmedizin, Tübingen, 72076, Germany|Childrens Regional Hospital Aglaia Kyriakou, Athens, 115 27, Greece|Aghia Sophia Children's Hospital; Pediatric Rheumatology Unit; 1st Department of Pediatrics, Athens, 11527, Greece|Rambam Medical Center, Haifa, 31096, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Schneider Children's Medical Center of Israel; Pediatrics Department, Petach Tikva, 49100, Israel|The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat-Gan, 52621, Israel|The Dana Children's Hospital, Tel Aviv, 64239, Israel|Ospedale Pediatrico Bambino Gesu, Roma, Lazio, 00165, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa Pediatria 1, Milano, Lombardia, 20122, Italy|ASST DI MONZA; Divisione Malattie Infettive, Monza, Lombardia, 20052, Italy|Instituto Nacional de Pediatria; Departmento de Neurologia, Mexico, 04530, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León, Monterrey, 64460, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, 80-214, Poland|Children Hospital, Olsztyn; Ward of Pediatric Hematology and Oncology, Olsztyn, 10-561, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 im. prof.Tadeusza Sokolowskiego, Szczecin, 71-242, Poland|Medical University of Silesia; Department of Pediatric Hematology and Oncology, Zabrze, 41-800, Poland|Tygerberg Hospital; Rheumatology, Cape Town, 7500, South Africa|WWCT Lakeview Hospital, Johannesburg, 1501, South Africa|Chris Hani Baragwanath Hospital, Johannesburg, 2013, South Africa|Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, 08950, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, 28007, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain Less <<
NCT01010087 Influenza A Virus PHASE2 TERMINATED 2025-05-11 Winnipeg Regional Health Autho... More >>rity; Health Sciences Centre, Winnipeg, Manitoba, R3E 0Z3, Canada Less <<
NCT01443806 Metabolic Disease PHASE4 COMPLETED 2025-12-12 The Faculty of Tropical medici... More >>ne,Mahidol University, Bangkok, 10400, Thailand Less <<
NCT05008679 Heart Failure UNKNOWN 2024-01-25 Tongji Hospital, Wuhan, Hubei,... More >> 430030, China Less <<
NCT01456234 Influenza PHASE4 TERMINATED 2025-05-13 Paradise Medical Clinic, St. J... More >>ohn's, Newfoundland and Labrador, Canada|Aviva Medical Clinical Trials Group, Burlington, Ontario, Canada|Co-Medica Research Network, Courtice, Ontario, Canada|Dr. Sameh Fikry Medicine Professional Corporation, Kitchener, Ontario, Canada|Schacter Medicine Professional Corporation, London, Ontario, Canada|Springbank Medical Centre, London, Ontario, Canada|Taunton Health Centre, Oshawa, Ontario, Canada|Steeple Hill Medical Centre, Pickering, Ontario, Canada|London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada|DCTM Clinical Trials Group Ltd., Strathroy, Ontario, Canada|Dr. Anil Gupta, Toronto, Ontario, M9V 4B4, Canada|Source Unique Research, Dollard des Ormeaux, Quebec, Canada|Omnispec Clinical Research Inc., Mirabel, Quebec, Canada|Metropolitan Clinical Research Centre, Montreal, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada Less <<
NCT01388439 Prematurity of Fetus COMPLETED 2025-01-11 St. Louis Children's Hosptial,... More >> St. Louis, Missouri, 63110, United States Less <<
NCT01037634 Influenza PHASE2 WITHDRAWN - -
NCT01546935 Influenza PHASE2|PHASE3 WITHDRAWN 2025-12-14 Queen Sirikit National Institu... More >>te of Child Health, Bangkok, 10400, Thailand|Faculty of Medicine Siriraj Hospital, Bangkok, 10700, Thailand Less <<
NCT02617784 End Stage Renal Disease PHASE1 COMPLETED 2025-06-02 Christchurch, 8011, New Zealan... More >>d Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.20mL

0.64mL

0.32mL

16.01mL

3.20mL

1.60mL

32.01mL

6.40mL

3.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories